要点提示
JAMA Oncol:输卵管卵巢切除术可降低携带BRCA致病基因突变女性的乳腺癌风险
Blood:固定持续时间、MRD指导的治疗方法可提高CLL患者的生存率
CCR:双抗血管生成药物一线治疗转移性结直肠癌,疗效持久且安全性可控
CCR:瑞戈非尼联合Avelumab可增加微卫星稳定型结直肠癌患者的抗肿瘤免疫力
新药:贝达药业第四代EGFR抑制剂获批临床
01
JAMA Oncol:输卵管卵巢切除术可降低携带BRCA致病基因突变女性的乳腺癌风险
02
Blood:固定持续时间、MRD指导的治疗方法可提高CLL患者的生存率
03
CCR:双抗血管生成药物一线治疗转移性结直肠癌,疗效持久且安全性可控
04
CCR:瑞戈非尼联合Avelumab可增加微卫星稳定型结直肠癌患者的抗肿瘤免疫力
05
新药:第四代EGFR小分子抑制剂获批临床
[1].Yun-Hee Choi,Mary Beth Terry,Mary B.Daly,et al.Association of Risk-Reducing Salpingo-Oophorectomy with Breast Cancer Risk in Women with BRCA1 and BRCA2 Pathogenic Variants.JAMA Oncology.Published on February 25,2021.
DOI:https://doi.org/10.1001/jamaoncol.2020.7995.
[2].Anne-Sophie Michallet,Rémi Letestu,Magali Le Garff-Tavernier,et al.A fixed-duration,measurable residual disease–guided approach in CLL:follow-up data from the phase 2 ICLL-07 FILO trial.Published:February 25,2021.https://doi.org/10.1182/blood.2020008164.
[3].Jennifer Mooi,Fiona Chionh,Peter Savas,et al.Dual Antiangiogenesis Agents Bevacizumab Plus Trebananib,without Chemotherapy,in First-line Treatment of Metastatic Colorectal Cancer:Results of a Phase II Study.Published:February 25,2021.DOI:10.1158/1078-0432.CCR-20-2714
[4].Sophie Cousin,Coralie Cantarel,Jean-Philippe Guegan,et al.Regorafenib-Avelumab Combination in Patients with Microsatellite Stable Colorectal Cancer(REGOMUNE):A Single-arm,Open-label,Phase II Trial.Published:February 25,2021.DOI:10.1158/1078-0432.CCR-20-3416.
[5].https://mp.weixin.qq.com/s/sMwmVWIQh1i9RrAdx7cuMQ
本文首发:医学界肿瘤频道
本文作者:肿瘤情报组
本文审核:于江泳 北肿瘤科 副主任医师
责任编辑:Sharon
版权申明
联系客服